Sun Pharmaceuticals Ltd is likely to complete the integration of Ranbaxy by end of next month if all regulatory approvals come as expected, according to its founder - Managing Director, Dilip S Shanghvi.

Speaking to newspersons on the sidelines of a book release function held here on Friday, Shanghvi said the fourth quarter results could actually reflect the numbers for the combined entity.

"We have the issue coming up in High Court on February 2, 2015. Once we get the approval, by middle of February, we should be able to close the deal and have a combined entity,’’ he said.

In April last year, Sun Pharma announced its plans to buy out Ranbaxy in a $4-billion (including $800-million debt), all-stock deal, in the process creating India’s largest drug company.

Asked on the key challenges in the process of integration, Shanghvi identified differences in product portfolio as one.

"Product portfolio (of Ranbaxy) would be different from that of us. Also they have significance presence in countries where we have only small presence. As I see, these are important challenges for the future business,’’ he said.

Shanghvi, who is known for his penchant and expertise for management of human resources feels that Sun Pharma would have to help people in Ranbaxy who made that company successful while making them confident about their future.

On the plans for a new acquisition, he said: "Next acquisition may take a little longer. It depends on the issues of integration, among others.’’

On the issues concerning alleged delays in new drug approvals from the US Food and Drug Administration, Shanghvi said the FDA was now looking at various initiatives including those qualify for early approvals on various parameters.

Related Topics
comment COMMENT NOW